MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Written by / Agency / Source: MDxHealth, Inc.
Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

ConfirmMDx Improves Prostate Cancer Diagnosis in African American Men - MDxHealth SA announced that results from a retrospective study demonstrated that its ConfirmMDx® for Prostate Cancer test improved the identification of African American men at risk for aggressive cancer missed by a prostate biopsy - MDxHealth.com
ConfirmMDx Improves Prostate Cancer Diagnosis in African American Men

 

NewswireToday - /newswire/ - Irvine, CA, United States, 2017/05/12 - MDxHealth SA announced that results from a retrospective study demonstrated that its ConfirmMDx® for Prostate Cancer test improved the identification of African American men at risk for aggressive cancer missed by a prostate biopsy - MDxHealth.com. NYSE Euronext: MDXH

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services / Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

MDxHealth SA today announced that results from a retrospective study demonstrated that its ConfirmMDx® for Prostate Cancer test improved the identification of African American men at risk for aggressive cancer missed by a prostate biopsy. The study findings were presented in a podium session at the 2017 American Urological Association (AUA) Annual Meeting in Boston, Massachusetts in the US.

In the study of 211 African American men, the test successfully identified men with false-negative biopsy results, meaning cancer was missed in a previous prostate biopsy. Upon repeat biopsy, 38% of patients were diagnosed with prostate cancer, of which 33% were diagnosed with clinically significant disease (Gleason Score >7). Importantly, when the test was negative, it yielded a powerful 96% negative predictive value for aggressive prostate cancer, confirming the test's strong performance as previously reported.

"African American men have a greater risk of clinically significant prostate cancer than the general population; however, because their cancer behaves differently on a molecular level, we do not yet have a tool to safeguard against potentially fatal false-negative results," said Dr. Robert Waterhouse, study investigator and urologist at Carolina Urology Partners, North Carolina, US. "The findings from this study are critical because they demonstrate that we finally have a test that can help urologists accurately identify men at increased risk for aggressive disease in this population. It's reassuring that ConfirmMDx provides consistently accurate results across ethic groups."

African American men have the highest incidence of prostate cancer and are roughly 1.6 times more likely to develop the disease than Caucasians and 2.7 times more likely than Asian Americans.2

"Our mission is to deliver molecular diagnostic solutions for patients with urologic cancers, so it is fulfilling to see that our lead product, ConfirmMDx serves African American men, who have a greater risk for potentially lethal disease," said Dr. Jan Groen, CEO of MDxHealth. "The data demonstrate that the test performance is consistent with our previous validation studies, and can therefore provide physicians and their patients with greater peace of mind when making decisions on the need for a biopsy."

Additional data on the clinical utility of ConfirmMDx will be presented in a moderated poster session on 13 May, abstract #MP33-10.

About ConfirmMDx for Prostate Cancer
ConfirmMDx for Prostate Cancer is the first epigenetic, and only tissue-based test in the 2016 NCCN Guidelines for early detection of prostate cancer which addresses false negative biopsy concerns. It is the only molecular diagnostic test that provides a very high negative predictive value (NPV) of 96% for clinically significant prostate cancers, and 90% NPV for all prostate cancers, as well as prostate mapping of the test results to help guide repeat biopsies. Each year, more than 1 million American men undergo an invasive prostate biopsy with a negative result, however approximately 30% of those men have prostate cancer. The current standard of care for prostate biopsy procedures samples less than 1% of the prostate, leaving men at risk for undetected cancer and leading to a high rate of repeat biopsies, even on cancer-free men. ConfirmMDx for Prostate Cancer helps urologists identify low-risk men who may forego an unnecessary repeat biopsy and high-risk men who may benefit from intervention. ConfirmMDx has qualified for Medicare reimbursement and covered by numerous private health insurance plans.

About MDxHealth
MDxHealth (mdxhealth.com) is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California.

References:
1. van Neste L, et al. (2017) Clinical Performance of an Epigenetic Assay to Identify Occult High-Grade Prostate Cancer in African American Men. American Urological Association (EAU) Annual Meeting. Abstract # PD07-04. 12 May 2017.
2. Surveillance, Epidemiology, and End Results (SEER) database, 2000-2013, National Cancer Institute.

This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Medical Services / Equipment Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: MDxHealth, Inc.

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]  / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 
 
  Your Banner Ad showing on ALL
Medical Services / Equipment articles,
CATCH Visitors via Your Competitors Announcements!


ConfirmMDx Improves Prostate Cancer Diagnosis in African American Men

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
Publisher Contact: Shalon Roth - MDxHealth.com 
+44(0)73 9390 6278 info[.]mdxhealth.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any MDxHealth, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Medical Services / Equipment via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From MDxHealth, Inc. / Company Profile


Read Medical Services / Equipment Most Recent Related Newswires:

Bruker Introduces Updated B.I.QUANT-UR™ Module for Fully Validated Metabolite Quantification in Urine Using NMR
SCHOTT Extends SyriQ BioPure® Syringe Format to Enable Optimized Administration
Hand Hygiene Market Will Reach .98 Billion in the US and EU5 with High Adoption of Gamification Finds Frost & Sullivan
Rise in Pharmaceutical Applications to Foster Demand for Mass Spectrometers in Europe Finds Frost & Sullivan
Cala Health Applauded by Frost & Sullivan for Revolutionizing the Essential Tremor Market with its Body-worn Neuromodulation Therapy, Cala Trio™
Withings Launches ScanWatch - the First Hybrid Smartwatch to Combine Medical Grade Electrocardiogram and Sleep Apnea Detection
Bruker Introduces Dedicated Light-Sheet Microscope for Highly Multiplexed 3D Cell Culture Live Imaging
Inkwood Research Publishes Global 3D Cell Culture Market Forecast 2019-2027
Bruker’s PeakForce Tapping is Fastest Growing AFM Mode
Philips Commended by Frost & Sullivan for Advancing Access to Affordable, High-quality Care through Its Incisive CT Platform
ZOLL to Showcase Portfolio of Advanced Resuscitation Technologies for the Workplace At A+A Congress 2019
Bruker Launches Ultrafast FTIR Imaging Microscope LUMOS II
Drug Delivery Devices Offering Enhanced Connectivity to Find Higher Uptake Among Hospitals finds Frost & Sullivan
Global Inorganic Scintillators Market Projected to Grow At 5.28% CAGR Through 2027 Reports Inkwood Research
Rising Aging Population Projects the Global Hearing Aids Market At 5.42% CAGR by 2027 Reports Inkwood Research

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  RightITnow, Inc.

Visit  BizJobs.com





 
  ©2020 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)